OFM
Omega Fund Management Portfolio holdings
AUM
$154M
This Quarter Return
+5.26%
1 Year Return
-32.78%
3 Year Return
+82.35%
5 Year Return
+29.08%
10 Year Return
+90.46%
AUM
$131M
AUM Growth
+$131M
(-2.8%)
Cap. Flow
-$1.87M
Cap. Flow
% of AUM
-1.43%
Top 10 Holdings %
Top 10 Hldgs %
99.55%
Holding
11
New
–
Increased
–
Reduced
3
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$757K |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$591K |
| 3 |
Editas Medicine
EDIT
|
$524K |
Sector Composition
| 1 | Healthcare | 70.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
| $36.9M | 28.17% | 1,229,512 | – | – |
|
|
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $33.8M | 25.83% | 2,600,410 | – | – |
|
|
EGLT
3
DELISTED
Egalet Corporation
EGLT
| $22M | 16.79% | 2,889,926 | – | – |
|
4
FibroGen
FGEN
$47.8M
| $17M | 12.99% | 822,175 | – | – |
|
|
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $8.08M | 6.17% | 1,145,890 | – | – |
|
6
ESSA Pharma
EPIX
$11.4M
| $4.67M | 3.56% | 1,696,969 | – | – |
|
|
PVLA
7
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $3.38M | 2.58% | 1,848,984 -413,848 | -18% | -$757K |
|
8
Protara Therapeutics
TARA
$120M
| $2.33M | 1.78% | 250,000 | – | – |
|
|
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.31M | 1% | 223,457 | – | – |
|
|
10
Editas Medicine
EDIT
$231M
| $892K | 0.68% | 66,162 -38,846 | -37% | -$524K |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $585K | 0.45% | 301,477 -304,623 | -50% | -$591K |
|